Result of AGM
December 09 2009 - 4:34AM
UK Regulatory
TIDMNPH
RNS Number : 8309D
Neuropharm Group PLC
09 December 2009
+------------------------------------------+------------------------------------+
| For immediate release | 9 December 2009 |
+------------------------------------------+------------------------------------+
Neuropharm Group Plc
("Neuropharm" or "the Company")
Result of AGM
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on
neurodevelopmental disorders, held its Annual General Meeting earlier today at
which all resolutions were duly passed.
For further information please contact:
+-----------------------------------------------+--------------------+
| Neuropharm | + 44 (0) 1372 371 |
| | 171 |
+-----------------------------------------------+--------------------+
| Robert Mansfield, Chief Executive Officer | |
| Graham Yeatman, Chief Financial Officer | |
+-----------------------------------------------+--------------------+
| | |
+-----------------------------------------------+--------------------+
| Piper Jaffray Ltd. | + 44 (0) 20 3142 |
| | 8700 |
+-----------------------------------------------+--------------------+
| Neil Mackison, Rupert Winckler | |
+-----------------------------------------------+--------------------+
| | |
+-----------------------------------------------+--------------------+
| Buchanan Communications | + 44 (0) 20 7466 |
| | 5000 |
+-----------------------------------------------+--------------------+
| Mark Court | |
+-----------------------------------------------+--------------------+
Notes to Editors:
About Neuropharm
Neuropharm is a speciality pharmaceutical company focused on the development of
products for the treatment and management of neurodevelopmental disorders.
Please visit www.neuropharm.co.uk for further information.
Piper Jaffray, which is authorised and regulated by the Financial Services
Authority, is acting exclusively for Neuropharm and for no-one else in
connection with the matters referred to in this announcement and will not be
responsible to anyone other than Neuropharm for providing the protections
afforded to customers of Piper Jaffray nor for giving advice in relation to the
matters referred to in this announcement.
Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the
"Code"), if any person is, or becomes, "interested" (directly or indirectly) in
1% or more of any class of "relevant securities" of Neuropharm, all "dealings"
in any " relevant securities" of Neuropharm (including by means of an option in
respect of, or a derivative referenced to, any such "relevant securities") must
be publicly disclosed by no later than 3.30 pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the "offer period" otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
"interest" in "relevant securities" of Neuropharm, they will be deemed to be a
single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of Neuropharm by Neuropharm or by any of its "associates", must be
disclosed by no later than 12.00 noon (London time) on the London business day
following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.
"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the ownership or control of securities, or by virtue of any option in
respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, you should consult the Panel.
Rule 2.10
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, the
Company announces that it has 31,536,697 ordinary shares of 10 pence each in
issue and admitted to trading on the AIM market of the London Stock
Exchange plc. The International Securities Identification Number for the
ordinary shares is GB00B1NPJJ01.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFSFFSUSUSEDE
Neuropharm (LSE:NPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Neuropharm (LSE:NPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Neuropharm (London Stock Exchange): 0 recent articles
More Neuropharm News Articles